Bridgehead International has recently completed a substantial commercial due diligence assignment for the global private equity firm, The Riverside Company.
The target was a European pharmaceutical company with both marketed assets and a strong R&D pipeline.
William Jaworski, Senior Associate at Riverside commented, “Thanks in part to the solid advice, analysis and pharmaceutical industry experience demonstrated by Bridgehead, we secured a promising investment in a fast-growing European pharmaceutical company. The combination of Bridgehead’s in-depth understanding of the sector, coupled with their strong reporting and analytical skills, gave us everything we needed to know about the target’s product portfolio and its commercial capabilities and helped us find peace of mind regarding the strength of its development pipeline. We’ve been delighted with Bridgehead; the work was carried out on time, on budget and to an excellent standard. We would certainly use Bridgehead again for any future pharmaceutical consultancy work.”
Timothy Fitzgerald, CEO of Bridgehead International added, ‘Bridgehead’s expert team was able to provide a rapid, in depth assessment of the target’s business, ranging from financial projections, commercialization strategy, market access and pricing through to the research and development portfolio. It is very satisfying to see that our advisory work has contributed to this investment and we wish the company and its investors every success for the future’.